• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种在嗜酸性粒细胞中表达的新型前列腺素D2(PGD(2))受体。

A novel PGD(2) receptor expressed in eosinophils.

作者信息

Powell William S

机构信息

Meakins-Christie Laboratories, McGill University, 3626 St Urbain Street, Montreal, Quebec, Canada H2X 2P2.

出版信息

Prostaglandins Leukot Essent Fatty Acids. 2003 Aug-Sep;69(2-3):179-85. doi: 10.1016/s0952-3278(03)00079-6.

DOI:10.1016/s0952-3278(03)00079-6
PMID:12895601
Abstract

PGD(2) is a major product of arachidonic acid metabolism by mast cells and is released in the lungs following allergen challenge. Activation of the classic PGD(2) receptor (DP receptor) results in stimulation of adenylyl cyclase, resulting in inhibition of platelet aggregation and smooth muscle relaxation. A second PGD(2) receptor has recently been identified and designated as the DP(2) receptor, or chemoattractant receptor-homologous molecule expressed on Th2 cells. PGD(2) acts through the DP(2) receptor to induce eosinophil chemotaxis, actin polymerization, calcium mobilization, and adhesion molecule expression. The most potent DP(2) receptor agonist yet identified is 15R-methyl-PGD(2), which has the unnatural R configuration at C(15). 15-Deoxy-Delta(12,14)-PGJ(2) is also a potent DP(2) receptor agonist that activates eosinophils at concentrations much lower than those required for its anti-inflammatory effects. Because of its critical location in the lung and its potent effects on eosinophils, PGD(2) may be an important proinflammatory mediator in asthma.

摘要

前列腺素D2(PGD(2))是肥大细胞花生四烯酸代谢的主要产物,在变应原激发后于肺中释放。经典前列腺素D2受体(DP受体)的激活会刺激腺苷酸环化酶,从而抑制血小板聚集并使平滑肌舒张。最近已鉴定出第二种前列腺素D2受体,并将其命名为DP(2)受体,即Th2细胞上表达的趋化因子受体同源分子。PGD(2)通过DP(2)受体发挥作用,诱导嗜酸性粒细胞趋化、肌动蛋白聚合、钙动员以及黏附分子表达。目前已鉴定出的最有效的DP(2)受体激动剂是15R-甲基-PGD(2),其在C(15)处具有非天然的R构型。15-脱氧-Δ(12,14)-PGJ(2)也是一种有效的DP(2)受体激动剂,其激活嗜酸性粒细胞的浓度远低于其发挥抗炎作用所需的浓度。由于其在肺中的关键位置以及对嗜酸性粒细胞的强效作用,PGD(2)可能是哮喘中一种重要的促炎介质。

相似文献

1
A novel PGD(2) receptor expressed in eosinophils.一种在嗜酸性粒细胞中表达的新型前列腺素D2(PGD(2))受体。
Prostaglandins Leukot Essent Fatty Acids. 2003 Aug-Sep;69(2-3):179-85. doi: 10.1016/s0952-3278(03)00079-6.
2
15-Deoxy-delta 12,14-prostaglandins D2 and J2 are potent activators of human eosinophils.15-脱氧-Δ12,14-前列腺素D2和J2是人类嗜酸性粒细胞的强效激活剂。
J Immunol. 2002 Apr 1;168(7):3563-9. doi: 10.4049/jimmunol.168.7.3563.
3
Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor.前列腺素D2是一种对人类嗜酸性粒细胞有强大趋化作用的物质,它通过一种新型DP受体发挥作用。
Blood. 2001 Sep 15;98(6):1942-8. doi: 10.1182/blood.v98.6.1942.
4
15R-methyl-prostaglandin D2 is a potent and selective CRTH2/DP2 receptor agonist in human eosinophils.15R-甲基前列腺素D2是一种对人嗜酸性粒细胞具有强效和选择性的CRTH2/DP2受体激动剂。
J Pharmacol Exp Ther. 2003 Jan;304(1):349-55. doi: 10.1124/jpet.102.042937.
5
Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils.OC000459 是一种强效、选择性和口服有效的 D 前列腺素受体 2 拮抗剂,可抑制肥大细胞依赖性 T 辅助 2 淋巴细胞和嗜酸性粒细胞的激活。
J Pharmacol Exp Ther. 2012 Feb;340(2):473-82. doi: 10.1124/jpet.111.187203. Epub 2011 Nov 21.
6
Agonist and antagonist effects of 15R-prostaglandin (PG) D2 and 11-methylene-PGD2 on human eosinophils and basophils.15R-前列腺素(PG)D2和11-亚甲基-PGD2对人嗜酸性粒细胞和嗜碱性粒细胞的激动剂和拮抗剂作用。
J Pharmacol Exp Ther. 2007 Jan;320(1):173-9. doi: 10.1124/jpet.106.111062. Epub 2006 Oct 13.
7
Delta 12-prostaglandin J2, a plasma metabolite of prostaglandin D2, causes eosinophil mobilization from the bone marrow and primes eosinophils for chemotaxis.Delta 12-前列腺素J2是前列腺素D2的血浆代谢产物,可导致嗜酸性粒细胞从骨髓中动员出来,并使嗜酸性粒细胞对趋化性产生预激作用。
J Immunol. 2003 May 1;170(9):4752-8. doi: 10.4049/jimmunol.170.9.4752.
8
Co-operative signalling through DP(1) and DP(2) prostanoid receptors is required to enhance leukotriene C(4) synthesis induced by prostaglandin D(2) in eosinophils.需要通过 DP(1)和 DP(2)前列腺素受体的合作信号传导来增强前列腺素 D(2)诱导嗜酸性粒细胞中白三烯 C(4)的合成。
Br J Pharmacol. 2011 Apr;162(8):1674-85. doi: 10.1111/j.1476-5381.2010.01086.x.
9
CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist responses.[3H]雷马曲班的CRTH2特异性结合特性及其对前列腺素D2、15-脱氧-Δ12,14-前列腺素J2和吲哚美辛诱导的激动剂反应的影响。
Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7. doi: 10.1016/j.ejphar.2005.09.005. Epub 2005 Oct 27.
10
Effects of prostaglandin D2, 15-deoxy-Delta12,14-prostaglandin J2, and selective DP1 and DP2 receptor agonists on pulmonary infiltration of eosinophils in Brown Norway rats.前列腺素D2、15-脱氧-Δ12,14-前列腺素J2以及选择性DP1和DP2受体激动剂对棕色挪威大鼠肺部嗜酸性粒细胞浸润的影响。
J Pharmacol Exp Ther. 2005 Apr;313(1):64-9. doi: 10.1124/jpet.104.079079. Epub 2004 Dec 8.

引用本文的文献

1
Eosinophil recruitment and activation: the role of lipid mediators.嗜酸性粒细胞募集和激活:脂类介质的作用。
Front Pharmacol. 2013 Mar 22;4:27. doi: 10.3389/fphar.2013.00027. eCollection 2013.
2
PGH1, the precursor for the anti-inflammatory prostaglandins of the 1-series, is a potent activator of the pro-inflammatory receptor CRTH2/DP2.PGH1,1 系列抗炎前列腺素的前体,是促炎受体 CRTH2/DP2 的强效激活剂。
PLoS One. 2012;7(3):e33329. doi: 10.1371/journal.pone.0033329. Epub 2012 Mar 19.
3
Immunoprotective properties of primary Sertoli cells in mice: potential functional pathways that confer immune privilege.
小鼠初级支持细胞的免疫保护特性:赋予免疫特权的潜在功能途径。
Biol Reprod. 2012 Jan 10;86(1):1-14. doi: 10.1095/biolreprod.110.089425. Print 2012 Jan.
4
Dominant negative actions of human prostacyclin receptor variant through dimerization: implications for cardiovascular disease.人前列环素受体变异体通过二聚化产生显性负效应:对心血管疾病的影响。
Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):1802-9. doi: 10.1161/ATVBAHA.110.208900. Epub 2010 Jun 3.
5
Aspirin sensitivity and desensitization for asthma and sinusitis.阿司匹林敏感性以及针对哮喘和鼻窦炎的脱敏治疗
Curr Allergy Asthma Rep. 2009 Mar;9(2):155-63. doi: 10.1007/s11882-009-0023-4.